TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change of Bishop Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of glaucoma drugs required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Risk for detecting lung cancer
Endpoint domain: Mortality/survival
Primary endpoint: gingivitis score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding index score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-free status after chemotherapy and surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma content of c9t11 CLA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: triglycerides concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximal gripping force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HOMAIR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute side effects
Endpoint domain: Adverse events/effects
Primary endpoint: PCO intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neodymium:yttrium-aluminium-garnet laser treatment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Interleukin 6 removal efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor necrosis factor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin 10 removal efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: relative rate of clinic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: serum vitamin E levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Ventilation (TTV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for i-gel over Aura-i
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Illness-related anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abstinence rates in patients with SAMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental cost-effectiveness ratio per additional abstinent patient with an SAMC
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Histamine levels in shed blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PGE2 levels in shed blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Alterations of dark adaptability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical silent period potentiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decrease in anxiety sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in automatic thoughts
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Injection pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of norepinephrine and vanillylmandelic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: urge to drink
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC and AUCss for temocaprilat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CL(R) for temocapril and temocaprilat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Light sedation compliance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of VAO requiring membranectomy
Endpoint domain: Adverse events/effects
Primary endpoint: Development of glaucoma
Endpoint domain: Adverse events/effects
Primary endpoint: Radiographically confirmed pneumonia risk
Endpoint domain: Adverse events/effects
Primary endpoint: creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: evaluated treatment as less negative
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: anticipatory distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: anticipated pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total E dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total DAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Contrast medium used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Core temperature change after anesthesia induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final core temperature at the end of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-free survival at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Improved ASIA impairment grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Risk of non-fatal myocardial infarction and stroke
Endpoint domain: Mortality/survival
Primary endpoint: maximum percentage decrease in FEV1 after the 4-hour exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Objective improvement in measured urinary leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Subjective improvement in the amount of urinary leakage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Life-threatening illnesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensive care admissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensive care days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median TFFS (Time to First Treatment Failure)
Endpoint domain: Mortality/survival
Primary endpoint: Median OS (Overall Survival)
Endpoint domain: Mortality/survival
Primary endpoint: All grade toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived effectiveness of repellents
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness to continue repellent use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in serum creatinine (SCr) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Median duration of tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effective treatment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative culture rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FBF (%FBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cGMP (%cGMP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Venous diameter reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: D-dimer increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ratio in RMS of facial muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to first demand for analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious asthma exacerbations requiring systemic corticosteroids
Endpoint domain: Adverse events/effects
Primary endpoint: FEV1 measured 2 h after dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Predose trough FEV1 measured at all visits after baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: development of renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: number of extrapulmonary organ failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost per patient treated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: costs of community mental health services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diabetes control problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BP (Body Pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PF (Physical Functioning)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bacterial contamination of the ventilator side
Endpoint domain: Adverse events/effects
Primary endpoint: Volume of surgical specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increase in cancer-preventive lifestyle behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to rescue or discontinuation due to inadequate glycaemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak serum concentration of risperidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the serum concentration-time curve of risperidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of impaired renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: accidental extubation
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of MIP-1β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MIO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chondrocyte mortality
Endpoint domain: Mortality/survival
Primary endpoint: incremental plasma glucose area under the curve (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Estradiol (E(2)) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Evidence of ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: RBC life span
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: morphology and distribution of RBC membrane protein granules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: erythrocyte mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maximal oxygen consumption during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linkage to care at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HIV viral suppression at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Desaturation below 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MASI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: colorimetric values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: melanin assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: acute and chronic respiratory disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Knowledge scores of health visitors regarding walker use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jump performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of C. albicans colonies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean fall in systolic BP (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean fall in diastolic BP (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean blood loss of the thoracic component
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median post-operative stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in diarrheal morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ocular allergy symptom and sign scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DVT frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: F1+2, TAT, and MP‐TF indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: fTFPI levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the drug concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in E/e' ratio from baseline to peak stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in e' velocity from baseline to peak stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: facial recognition performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: urinary flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral palsy of any severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Moderate-to-severe cerebral palsy at 2 years of corrected age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean toe pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Intraclass correlation coefficient for toe pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cohen's Kappa for diagnostic classification of PAD
Endpoint domain: Adverse events/effects
Primary endpoint: serum alkaline phosphatase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum aspartate aminotransferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative global strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Use of motivational interviewing (MI) for tobacco cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regulation of patient behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GHb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Microalbuminuria concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: A1c percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean total and unconjugated bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Gamma‐glutaryl transferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: sensory dermatomal block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain sensitization response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in depression, anxiety, frustration, and fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hypoglycemia event rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of hypotension during dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in systolic and diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality rate due to intolerance to duodenal feeding
Endpoint domain: Mortality/survival
Primary endpoint: Total rotigotine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life for unconjugated rotigotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal elimination of total rotigotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Acne-symptoms domain improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Numbers of EPCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbers of clusters of EPCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adhesive EPCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migratory EPCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAFF expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Th2 cytokine expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-10 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tunnel widening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean YMR score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean HAM-D 28 rating reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean MADRS rating reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Twenty-four hour standard deviation of sinus intervals (SDNN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in serum creatinine >0.5 mg/dL at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Partial response (PR) and stable disease (SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: absolute UEUA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: fractional UEUA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lacrimal duct obstruction (LDSO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale (VAS) scores for nasal obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal cavity volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCA (Middle Concha Area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombin generation (prothrombin fragment 1.2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Optic Nerve Sheath Diameter (ONSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: test duration in memory tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of tool-related DRPs identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of reactive nonstress tests (NSTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve a reactive NST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fractional area change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mVcfc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: end-systolic wall stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean number of patients with CRBSI per 1000 patients
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality associated with IL-6 levels
Endpoint domain: Mortality/survival
Primary endpoint: Duration of block above T10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Transient neurological symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Cauda equina-like syndrome
Endpoint domain: Adverse events/effects